![]() FDA clears first new weight- loss pill in 1. WASHINGTON (AP) . The drug should be used in combination with a healthy diet and exercise. ![]() ![]() Orexigen Therapeutics Inc. The FDA today approved a new weight-loss drug for people who are obese or overweight with at least one weight-related health condition, easing a burden tha Xconomy Xperience EXOME National Regions. Arena Pharma: Weight-Loss Drug Approved! Adam Feuerstein Jun 27, 2012 2:56 PM EDT Updated with new information throughout. The FDA cleared use of the company's Stratus sinus device with saline solution, but a Department of Justice statement said the company never intended to use it this way. Instead, the company designed Stratus to be used with corticosteroids. Obesity Society President Patrick O'Neil said he's encouraged by the drug's approval because it underscores the notion that lifestyle changes alone are not enough to treat obesity. But if we had 1. 0 medicines that were all different and worked like this, we would have a real field. Louis Aronne, director of the weight loss program at Weill- Cornell Medical College. The FDA denied approval for Arena's drug in 2. The company resubmitted the drug with additional data earlier this year, and the FDA said there was little risk of tumors in humans. Arena and its partner Eisai Inc. The cocktail of phentermine and fenfluramine was a popular weight loss combination prescribed by doctors, though it was never approved by the FDA. In a rare move, the FDA explicitly stated in a press release that Belviq . But the FDA has delayed a decision on that pill until July. Shares of San Diego- based Arena Pharmaceuticals Inc. ![]() Shares of Mountain View, Calif.- based Vivus rose $1. Shares of Orexigen Therapeutics Inc., the third drugmaker with an obesity pill before the FDA, rose 2. Arena's studies showed that patients taking Belviq, known generically as lorcaserin, had modest weight loss. On average patients lost just 3 to 3. About 4. 7 percent of patients without diabetes lost at least 5 percent of their weight or more, which was enough to meet FDA standards for effectiveness. By comparison, average weight loss with Qnexa is 1. The FDA said patients should stop taking Belviq after three months if they fail to lose 5 percent of their body weight. Patients are unlikely to see any significant weight loss by staying with the drug. Side effects with the drug include depression, migraine and memory lapses. In May a panel of expert advisers to the FDA voted 1. Arena's drug, concluding that its benefits . Belviq is the first new prescription drug approved to treat obesity since Xenical's approval 1. Other safety failures for diet pills have continued to pile up in recent years. Four years ago Sanofi- Aventis SA discontinued studies of its highly anticipated pill Acomplia due to psychiatric side effects, including depression and suicidal thoughts. It's the first injectable drug approved for weight loss. Home Medications December 23, 2014. The FDA has approved three weight loss pills in recent years. It cleared Vivus Inc.'s Qsymia and Arena Pharmaceuticals Inc.'s Belviq in 2012 and granted approval to. The Food and Drug Administration (FDA) is advising consumers not to purchase or use Xtreme Fat Burner Capsules, a product promoted for weight loss. This product was identified by FDA during an examination of international mail shipments. FDA Approves New Weight-Loss Drug Saxenda cleared for use by adults who are obese or overweight and have at least one weight-related condition Please note: This article was published more than one year ago. The facts and conclusions presented may have. Holly Phillips explained on 'CBS This Morning.' 'It's actually been around for a couple of years to treat diabetes but was just approved by the FDA for weight loss in December. So this study really. The first new prescription diet drug in 13 years won Food and Drug Administration (FDA) approval on Wednesday, offering a new alternative to aid weight loss for the nearly one in three Americans who are considered obese. The new drug, called Belviq (lorcaserin), is. Takeda's obesity drug Contrave launches in US Clears cardiovascular safety hurdle to be third new weight-loss drug in recent months. In doing so it becomes the third weight-loss drug to be cleared by the FDA in recent years after a hiatus of more than a. In 2. 01. 0, Abbott Laboratories withdrew its drug Meridia after a study showed it increased heart attack and stroke.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |